KR20130043242A - Ｓｐａｒｃ 혈관형성 영역과 사용방법 - Google Patents

Ｓｐａｒｃ 혈관형성 영역과 사용방법 Download PDF

Info

Publication number
KR20130043242A
KR20130043242A KR1020137008481A KR20137008481A KR20130043242A KR 20130043242 A KR20130043242 A KR 20130043242A KR 1020137008481 A KR1020137008481 A KR 1020137008481A KR 20137008481 A KR20137008481 A KR 20137008481A KR 20130043242 A KR20130043242 A KR 20130043242A
Authority
KR
South Korea
Prior art keywords
tumor
sparc
seq
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137008481A
Other languages
English (en)
Korean (ko)
Inventor
부옹 트리에우
다니엘 크나우어
네일 데자이
Original Assignee
아브락시스 바이오사이언스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아브락시스 바이오사이언스, 엘엘씨 filed Critical 아브락시스 바이오사이언스, 엘엘씨
Publication of KR20130043242A publication Critical patent/KR20130043242A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020137008481A 2009-03-11 2010-03-11 Ｓｐａｒｃ 혈관형성 영역과 사용방법 Ceased KR20130043242A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15932209P 2009-03-11 2009-03-11
US61/159,322 2009-03-11
PCT/US2010/027041 WO2010105097A2 (en) 2009-03-11 2010-03-11 Sparc angiogenic domain and methods of use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117023819A Division KR20110139256A (ko) 2009-03-11 2010-03-11 Ｓｐａｒｃ 혈관형성 영역과 사용방법

Publications (1)

Publication Number Publication Date
KR20130043242A true KR20130043242A (ko) 2013-04-29

Family

ID=42729116

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137008481A Ceased KR20130043242A (ko) 2009-03-11 2010-03-11 Ｓｐａｒｃ 혈관형성 영역과 사용방법
KR1020117023819A Ceased KR20110139256A (ko) 2009-03-11 2010-03-11 Ｓｐａｒｃ 혈관형성 영역과 사용방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117023819A Ceased KR20110139256A (ko) 2009-03-11 2010-03-11 Ｓｐａｒｃ 혈관형성 영역과 사용방법

Country Status (13)

Country Link
US (2) US20120087910A1 (https=)
EP (1) EP2405932A4 (https=)
JP (1) JP2012520081A (https=)
KR (2) KR20130043242A (https=)
CN (2) CN103724417A (https=)
AU (1) AU2010224031B2 (https=)
BR (1) BRPI1009457A2 (https=)
CA (1) CA2755109A1 (https=)
IL (2) IL215089A0 (https=)
MX (1) MX2011009478A (https=)
NZ (1) NZ595528A (https=)
WO (1) WO2010105097A2 (https=)
ZA (1) ZA201107415B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013522235A (ja) * 2010-03-11 2013-06-13 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Ｓｐａｒｃ血管新生領域及びその使用法
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN120361186B (zh) * 2025-04-15 2025-12-30 北京大学口腔医学院 一种促进血管生成和组织再生的药物组合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000677A1 (en) * 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2006237613A1 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
US8440625B2 (en) * 2006-06-26 2013-05-14 University Of British Columbia Secreted protein acidic and rich in cysteine (SPARC) as chemotherapeutic sensitizers
ES2389828T3 (es) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Composiciones que comprenden polipéptidos SPARC

Also Published As

Publication number Publication date
CA2755109A1 (en) 2010-09-16
KR20110139256A (ko) 2011-12-28
BRPI1009457A2 (pt) 2016-03-01
CN102482334A (zh) 2012-05-30
AU2010224031A1 (en) 2011-10-06
EP2405932A2 (en) 2012-01-18
EP2405932A4 (en) 2012-08-22
US20140094416A1 (en) 2014-04-03
CN103724417A (zh) 2014-04-16
IL228795A0 (en) 2013-12-31
WO2010105097A2 (en) 2010-09-16
JP2012520081A (ja) 2012-09-06
US20120087910A1 (en) 2012-04-12
MX2011009478A (es) 2011-11-18
IL215089A0 (en) 2011-11-30
NZ595528A (en) 2013-10-25
WO2010105097A3 (en) 2010-11-04
AU2010224031B2 (en) 2013-05-02
AU2010224031A2 (en) 2011-10-20
WO2010105097A8 (en) 2011-05-26
ZA201107415B (en) 2012-06-27

Similar Documents

Publication Publication Date Title
KR101375026B1 (ko) 종양 및 세포의 제거 또는 파괴를 필요로 하는 다른 질환의 치료에 효과적인 펩티드
US20140094416A1 (en) Sparc angiogenic domain and methods of use
JP2013215191A (ja) 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド
US20220370560A1 (en) Ptd-smad7 therapeutics
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
US20130196929A1 (en) Secreted protein acidic and rich in cysteine (sparc) as chemotherapeutic sensitizers
JP2019523751A (ja) 前立腺癌の進行を予防または緩和する小型神経糸ペプチド
EP2630963A1 (en) SPARC angiogenic domain and methods of use
AU2013211470A1 (en) Sparc angiogenic domain and methods of use
HK1194403A (en) Sparc angiogenic domain and methods of use
HK1167664A (en) Sparc angiogenic domain and methods of use

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000